口服维生素K_1在新生儿的安全性研究  

Study on security of oral vitamin K1 to newborn infants

作　　者：梁友玲[1] 林超琼[1] 冯军坛[1] 

机构地区：[1]广西壮族自治区妇幼保健院,530003

出　　处：《儿科药学》2001年第4期9-10,共2页Journal of Pediatric Pharmacy

基　　金：卫生部科学研究基金课题(项目编号96-Z.490)

摘　　要：目的:探讨新生儿口服维生素K1(以下简称VK1)的安全性.方法:随机把128例足月顺产新生儿于生后1～12 h内分为喂服VK15 mg或2.5 mg 2组.全部病例均于生后三天内用试纸法筛查葡萄糖-6-磷酸脱氢酶活性,观察服VK1后出现黄疸的情况及其他不良反应.结果:全部病例无黄疸加重,未发现过敏反应,无明显的消化系统不良反应.结论:新生儿生后短时间内口服VK1片剂2.5～5 mg预防新生儿出血性疾病是安全的.objective: To study the security of oral dose of Vitamin K1 (Hereinafter referred to as VK1) given to normal newborn infants. Method: 128 cases of normal newborn infants, who randomly divided into two groups, orally took 2. 5 mg VK1 or took 5 mg VK1 within 1-12 hours separately when they were born. All 128 cases of normal newborn infants were checked by screening the activity of glucose-6-phosphate dehydrogenase (Hereinafter referred to as G-6-PD) with reagent paper method in the first three days and observed what happened to jaundice and other adverse drug reactions after taking VK1. Result: There was no severe jaundice and skin erythema occurred and there was no apparent minus effect occurred to the digestive system with taking VK1. Conclusion: It is security of oral VK1 to newborn infants with 2. 5 ~ 5 mg of oral VK1 in a short time to prevent the newborn infants from hemorrhagic diseases.

关 键 词：新生儿 维生素K1 口服 安全性 

分 类 号：R965.3[医药卫生—药理学] R977.26[医药卫生—药学]